80 institutions hold shares in Fennec Pharmaceuticals Inc. (FENC), with 4.41M shares held by insiders accounting for 16.94% while institutional investors hold 68.06% of the company’s shares. The shares outstanding are 25.91M, and float is at 21.27M with Short Float at 4.71%. Institutions hold 56.53% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Southpoint Capital Advisors Lp with over 4.08 million shares valued at $30.38 million. The investor’s holdings represent 15.68% of the FENC Shares outstanding. As of Dec 30, 2020, the second largest holder is Sonic Fund II, L.P. with 2.43 million shares valued at $18.13 million to account for 9.36% of the shares outstanding. The other top investors are Avoro Capital Advisors LLC which holds 1.67 million shares representing 6.42% and valued at over $12.44 million, while Eventide Asset Management LLC holds 4.31% of the shares totaling 1.12 million with a market value of $8.34 million.
Fennec Pharmaceuticals Inc. (NASDAQ: FENC) is -6.98% lower on its value in year-to-date trading and has touched a low of $4.80 and a high of $10.67 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FENC stock was last observed hovering at around $5.99 in the last trading session, with the day’s gains setting it 0.94% off its average median price target of $12.00 for the next 12 months. It is also 46.69% off the consensus price target high of $13.00 offered by 2 analysts, but current levels are 37.0% higher than the price target low of $11.00 for the same period.
Currently trading at $6.93, the stock is 0.07% and -7.28% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.21 million and changing 15.69% at the moment leaves the stock -7.05% off its SMA200. FENC registered 26.92% gain for a year compared to 6-month gain of 15.69%. The firm has a 50-day simple moving average (SMA 50) of $7.30 and a 200-day simple moving average (SMA200) of $7.46.
The stock witnessed a -5.52% loss in the last 1 month and extending the period to 3 months gives it a -7.10%, and is 11.59% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.94% over the week and 6.25% over the month.
Fennec Pharmaceuticals Inc. (FENC) has around 1 employees, a market worth around $177.34M and $0.17M in sales. Fwd P/E is 23.10. Distance from 52-week low is 44.37% and -35.05% from its 52-week high. The company has generated returns on investments over the last 12 months (-61.50%).
Fennec Pharmaceuticals Inc. (FENC) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Fennec Pharmaceuticals Inc. (FENC) is a “Buy”. 2 analysts offering their recommendations for the stock have an average rating of 1.50, where 0 rate it as a Hold and 0 think it is a “Overweight”. 2 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Fennec Pharmaceuticals Inc. is expected to release its quarterly report on 08/06/2021 and quarterly earnings per share for the current quarter are estimated at -$0.12.The EPS is expected to shrink by -19.00% this year, but quarterly earnings will post 60,452.90% year-over-year.
Fennec Pharmaceuticals Inc. (FENC) Insider Activity
A total of 0 insider transactions have happened at Fennec Pharmaceuticals Inc. (FENC) in the last six months, with sales accounting for 0 and purchases happening 0 times. The most recent transaction is an insider purchase by Southpoint Capital Advisors LP, the company’s 10% Owner. SEC filings show that Southpoint Capital Advisors LP bought 80,000 shares of the company’s common stock on May 04 at a price of $6.25 per share for a total of $0.5 million. Following the purchase, the insider now owns 4.08 million shares.
Fennec Pharmaceuticals Inc. disclosed in a document filed with the SEC on Apr 30 that Essetifin SPA (10% Owner) bought a total of 768,000 shares of the company’s common stock. The trade occurred on Apr 30 and was made at $6.25 per share for $4.8 million. Following the transaction, the insider now directly holds 3.99 million shares of the FENC stock.
Fennec Pharmaceuticals Inc. (FENC): Who are the competitors?
The company’s main competitors (and peers) include Eli Lilly and Company (LLY) that is trading 30.89% up over the past 12 months and Johnson & Johnson (JNJ) that is 21.78% higher over the same period. Sanofi (SNY) is 11.06% up on the 1-year trading charts. Short interest in the company’s stock has risen 8.87% from the last report on Feb 11, 2021 to stand at a total of 0.91 million short shares sold with a short interest ratio of 15.48.